Related references
Note: Only part of the references are listed.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
J. J. Shah et al.
BLOOD CANCER JOURNAL (2016)
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
Janet R. Wade et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Utility of Free and Total Target Measurements as Target Engagement and Efficacy Biomarkers in Biotherapeutic Development-Opportunities and Challenges
Songmao Zheng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE
Philip J. Lowe et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
WSES guidelines for management of Clostridium difficile infection in surgical patients
Massimo Sartelli et al.
WORLD JOURNAL OF EMERGENCY SURGERY (2015)
Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group
Christopher Evans et al.
AAPS JOURNAL (2015)
Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys
Weirong Wang et al.
AAPS JOURNAL (2014)
When Assay Format Matters: a Case Study on the Evaluation of Three Assay Formats to Support a Clinical Pharmacokinetic Study
Kun Peng et al.
AAPS JOURNAL (2014)
pH-dependent antigen-binding antibodies as a novel therapeutic modality
T. Igawa et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Yan Feng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
Dan Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
Valerie F. Cosson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
Herbert Struemper et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
Jasmine P. Davda et al.
MABS (2014)
Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL
E. Gibiansky et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies
L. Li et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
Membrane versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells
Shidrokh Ardestani et al.
CANCER RESEARCH (2013)
Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus
Herbert Struemper et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments
Ryan J. Hansen et al.
MABS (2013)
Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach
Lu Xu et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2013)
In Vitro Stoichiometry of Complexes between the Soluble RANK Ligand and the Monoclonal Antibody Denosumab
Kelly K. Arthur et al.
BIOCHEMISTRY (2012)
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
Leonid Gibiansky et al.
CLINICAL PHARMACOKINETICS (2012)
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
Abhijit Chakraborty et al.
CLINICAL PHARMACOKINETICS (2012)
Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
Jing Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Monoclonal antibodies directed against human FcRn and their applications
Gregory J. Christianson et al.
MABS (2012)
The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters Case studies
Saloumeh K. Fischer et al.
MABS (2012)
Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics
Jean W. Lee et al.
BIOANALYSIS (2012)
Bioanalytical Approaches to Quantify Total and Free Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
Jean W. Lee et al.
AAPS JOURNAL (2011)
Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
Liviawati Sutjandra et al.
CLINICAL PHARMACOKINETICS (2011)
PK-PD modeling of protein drugs: implications in assay development
Lorin K. Roskos et al.
BIOANALYSIS (2011)
State of the Art in Tumor Antigen and Biomarker Discovery
Klervi Even-Desrumeaux et al.
Cancers (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Next-Generation Model-Based Drug Discovery and Development: Quantitative and Systems Pharmacology
S. R. B. Allerheiligen
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets
Jasmine P. Davda et al.
MABS (2010)
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky et al.
NATURE BIOTECHNOLOGY (2010)
Therapeutic monoclonal antibody concentration monitoring: free or total?
Bing Kuang et al.
BIOANALYSIS (2010)
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations
Raymond G. Slavin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
Sian Lennon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
Peiming Ma et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-alpha Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Helen J. Lachmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Dimers and multimers of monoclonal IgGI exhibit higher in vitro binding affinities to Fcγ receptors
Yin Luo et al.
MABS (2009)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients
Anshu Marathe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms
Min-Soo Kim et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
W. Kievit et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs
Tadahiko Kohno et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2007)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath (R)) in patients with chronic lymphocytic leukaemia and its link to treatment response
D. R. Mould et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease
Yoko Furuya et al.
DRUG METABOLISM AND PHARMACOKINETICS (2007)
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
Guillaume Cartron et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors
Antoinette R. Tan et al.
CLINICAL CANCER RESEARCH (2006)
Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
Paul M. Beer et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab
D Ternant et al.
THERAPEUTIC DRUG MONITORING (2006)
Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis - A two-year prospective study (the DAMAGE study cohort)
BW Kirkham et al.
ARTHRITIS AND RHEUMATISM (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis
A Joshi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy
RG Hamilton et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach
GML Meno-Tetang et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
M Albitar et al.
CANCER (2004)
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
V Lemaire et al.
JOURNAL OF THEORETICAL BIOLOGY (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas
PV Beum et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
FJ Giles et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
T Manshouri et al.
BLOOD (2003)
Etanercept and infliximab associated with cutaneous vasculitis
ME McCain et al.
RHEUMATOLOGY (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis
P Barrera et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
MS Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
E Ädelroth et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
